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Shortness of  breath • THEME
The incidence of mental health problems in 
Australian society is high, especially that of anxiety and 
mood disorders. A recent population survey into the 
mental health of Australians found that 9.7% of adults 
reported symptoms in any 12 month period that met 
criteria for a diagnosis of one or more anxiety disorder.1 
The 12 month prevalence rate is close to the lifetime 
prevalence rate of these disorders (10.2%), indicating 
a high degree of chronicity.1 Seventy-two percent of 
these people did not access professional mental health 
assistance. Of those that did, many initially consulted 
their general practitioner. 
 Panic disorder (PD) is one of the most common of 
the anxiety disorders, affecting approximately 2.4% of 
the population during any 12 month period.2 Patients 
with PD often present to their GP seeking an organic 
explanation for their symptoms. The DSM-IV diagnostic 
criteria for PD are detailed in Table 1.3 
Comorbidity/complications
Panic disorder is associated with an increased risk of 
psychiatric morbidity (particularly major depression).4 
One-third to half of patients are depressed at initial 
presentation,5 and many also suffer from post-traumatic 
stress disorder (PTSD) and social phobia. Panic disorder 
is also associated with chronic medical conditions6 
(including mitral valve prolapse, migraine, and labile 
hypertension), overuse of medical services,7,8 suicide 
attempts,9 financial dependency, marital problems, 
alcohol and substance abuse,10,11 and impaired vocational 
and social functioning.4,11,12 Additionally, PD can coexist 
with independent physical disorders that may complicate 
the clinical picture, especially where these disorders 
impact on cardiac or respiratory function.
BACKGROUND Panic disorder (PD) is common 
in the community and contributes to significant 
distress and decreased quality of  life for people 
who suffer from it. Most people with PD will 
present in the first instance to their general 
practitioner or hospital emergency department 
for assistance, often with a focus on somatic 
symptoms and concerns. 
OBJECTIVE This article aims to assist the GP 
to manage this group of  patients by providing an 
outline of  aetiology, approaches to assessment, 
and common management strategies.
DISCUSSION Although GPs have an important 
role to play in ruling out any causal organic basis 
for panic symptoms, the diagnosis of  PD can 
usually be made as a positive diagnosis on the 
basis of  careful history taking. Thorough and 
empathic education is a vital step in management. 
The prognosis for PD can be improved by lifestyle 
changes, specific psychological techniques, and 
the judicious use of  pharmacotherapy. 
Managing panic 
disorder in general 
practice David Austin
BBus, GDipPsychStuds, 
GDipAppSci, is a 
registered psychologist, 
and Research Fellow, 






MD, FRACGP, is Senior 
Research Fellow, 
Department of General 
Practice, Monash 
University, Victoria, 
and Honorary Senior 
Lecturer, Institute 




MRACMA, is Senior 
Research Fellow, Alfred 
Psychiatric Research 
Centre, Alfred Hospital 
Melbourne, and Senior 





BA, DPsych (clin), is a 
registered psychologist, 
and Research Fellow, 
Department of General 
Practice, Monash 
University, Victoria.
564 3Reprinted from Australian Family Physician Vol. 34, No. 7, July 2005
Theme: Managing panic disorder in general practice
Aetiology
Panic disorder appears to have both genetic (and/
or familial) and psychological contributions to its 
development. A review and meta-analysis of the 
genetic epidemiology of PD13 found that both twin and 
family studies suggested a strong familial component, 
with the risk of PD among first degree relatives of 
PD sufferers being about 10% (compared to 2.1% in 
comparison relatives). Furthermore, twin studies reveal 
consistent findings attributing 30–40% of variance in 
PD liability to genetics, with the remaining variance 
coming from individual specific environmental factors. 
 Other research suggests that psychological variables 
influence the emergence of panic. Cognitive models of 
panic14 propose that panic attacks are the end result of 
a positive feedback loop whereby physical sensations 
are responded to with overwhelming anxiety, 
which thereby exacerbates the original symptoms 
and consequently the degree of anxious arousal, 
culminating ultimately in a panic attack (Figure 1). In 
particular, the development of PD is presumed to be 
the result of the person believing that symptoms of 
anxious arousal herald the imminent occurrence of a 
psychological or medical emergency.
 A personality variable known as ‘anxiety sensitivity’15 
has been consistently found to be associated with this 
type of cognitive bias, and with PD.16,17 It refers to a belief 
that symptoms of anxiety are in some way dangerous 
or likely to lead to something ‘bad’ happening. This 
personality variable appears to be independent of panic 
experience (ie. one does not need to have experienced 
a panic attack to have high anxiety sensitivity). People 
with high anxiety sensitivity are typically hypervigilant for 
variations and extremes in bodily functions/sensations, 
and have unrealistic expectations for the stability of 
those functions/sensations.  
 Behavioural perspectives18 state that individuals 
with PD have a genetically based biological vulnerability 
(ie. ‘hard wired’ to respond to the stress of negative 
life events with exaggerated neurobiological activity). 
This neurobiological over-reaction or false alarm occurs 
because such individuals perceive life stressors as if 
they were truly dangerous or life threatening. In some 
of these individuals, the initial false alarm becomes 
associated with the somatic sensations that accompany 
feelings of anxiety (eg. dizziness, palpitations).
 Although the cognitive and behavioural perspectives 
differ, both acknowledge the key role played by overanxious 
responding (both cognitively and behaviourally) to somatic 
stimuli. Much of the focus of cognitive behavioural therapy 
(CBT) is on analysing and correcting this response, through 
a process known as cognitive restructuring (Table 2) and 
graded exposure (Table 3).
The role of  the GP 
The GP’s role is determined by the nature of the 
presentation, but will usually involve detailed 
assessment, in particular relating to possible organic 
causes for the patient’s symptoms. Additionally, the 
GP has an important role to play in educating the 
patient about the nature of panic and determining a 
management plan which may include lifestyle changes, 
psychological interventions, pharmacotherapy and/or 
referral to a psychiatrist or allied health provider.
Assessment 
The assessment of panic by the GP requires a high 
Table 1. Key definitions3
Panic attack: A discrete period of intense fear or discomfort, in which four 
or more of the following symptoms developed abruptly and reached a peak 
within 10 minutes:
• palpitations, pounding heart, or accelerated heart rate
• sweating
• trembling or shaking
• sensation of shortness of breath or smothering
• feeling of choking
• chest pain or discomfort
• nausea or abdominal distress
• feeling dizzy, unsteady, light headed, or faint
•  derealisation (feelings of unreality) or depersonalisation (being detached 
from oneself)
• fear of losing control or going crazy
• fear of dying
• parasthesis (numbness or tingling sensations)
• chills or hot flushes
Panic disorder: The presence or recurrent, unexpected panic attacks 
followed by at least 1 month of persistent concern about having another 
panic attack, worry about the possible implications or consequences of the 
attacks, or a significant behavioural change related to the attacks
Agoraphobia: Anxiety about being in places or situations from which 
escape might be difficult or in which help may not be available in the event 
of having a panic attack or panic-like symptoms. The anxiety typically leads 
to a pervasive avoidance of a range of situations that may include being 
alone outside the home or being home alone, being in a crowd of people, 
travelling in a car, bus or airplane or being on a bridge or in an elevator 
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level of skill and sensitivity. On the one hand, the 
GP assumes prime responsibility for thoroughly 
investigating possible organic causes for panic 
symptoms, and on the other, the GP is trying to 
reassure patients who may have a high level of concern 
that they have a life threatening condition. Additionally, 
patients have varying degrees of acceptance of 
psychological diagnoses. The assessment of panic 
therefore requires the GP to put into practice 
sophisticated clinical and communication skills. 
 Assessment should include a full biopsychosocial 
evaluation, even if this requires a number of 
consultations, so as to: 
• arrive at a psychological formulation of the problem 
(why is this patient ill with this symptom at this 
time?), and 
• detect common comorbidities such as depression, other 
anxiety disorders and substance dependence/abuse. 
Key questions should explore the nature and frequency 
of the panic attacks, whether they are cued or 
spontaneous and whether agoraphobia has developed 
(Table 4).
 Structured assessment instruments such as the 
Panic Disorder Severity Scale,19 Mobility Inventory,20 
Body Sensations Questionnaire,21 and a patient ‘panic 
diary’ to record time and frequency of attacks, severity, 
and situational contexts can be useful. Such tools assist 
both patient and doctor to better understand the nature 
and specifics of the disorder. 
 Physical examination and investigation will be guided 
by the clinical presentation (Table 5). The threshold for 
investigating patients should be lowered where: 
• the clinical presentation is atypical 
• there is a sudden onset with no previous psychiatric 
history
• first presentation at age over 45 years, and 
• episodes which result in actual, rather than feared, 
collapse and/or loss of consciousness. 
Chest pain is common during a panic attack, although 
if it is ischaemic in character, it should be investigated 
appropriately, as PD has been associated with coronary 
spasm and may exacerbate pre-existing ischaemic 
heart disease.23  
Management 
Psycho-education
General practitioners are skilled at explaining illness to 
patients in a manner that takes into account their cultural 
and health beliefs. Clear explanation of PD is a key step 
of management. A number of educational resources 
are available (see Resources). Often presenting patients 
with a diagram of the panic cycle (Figure 1) assists them 
to understand and accept their diagnosis. 
Lifestyle changes
A number of lifestyle/behavioural changes have been 
shown to assist patients with PD. The use of stimulants 
such as caffeine should be avoided, as should excessive 
use of any substance or medication likely to complicate 
recovery. Regular moderate exercise has been 
shown to reduce negative affect in the short term, 
although some patients may find the resultant physical 
arousal anxiety provoking. It is important to manage 
life stresses appropriately rather than avoid anxiety 
provoking stimuli or situations, as avoidance increases 
the chronicity of the condition.
Psychological interventions
Cognitive behavioural therapy
Clinical trials have shown that multi-element treatment 
protocols for panic disorder, based on CBT principles, 
enable 75–95% of patients to be panic free following 
treatment, and that those improvements are maintained 
for at least 2 years.24–26 Significantly, the efficacy of 
this program does not appear to be compromised 
when patients have comorbid depression,29 nor when 
it is transferred from controlled research settings to the 
'real world' clinic setting.30 
 Cognitive behavioural therapy is better tolerated, has 
lower drop out rates, superior symptom control and 
reduced relapse rates compared to pharmacological 
treatments, including benzodiazepines (BZDs) and 
Figure 1. The panic cycle
Anxiety/panic
•  Hypervigilant for bodily 
sensations
•  Sympathetic nervous 
system arousal
Physical sensations
•  Feeling dizzy, faint
• Pounding heart
•  Shortness of breath
•  Feeling unreal or ‘spaced out’
Anxiety/panic
• ‘I’m going to faint’
• ‘I’m going to have a heart attack’
•  ‘I’m not going to be able to breathe‘
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antidepressants such as imipramine.31–34 
 A recent review on panic treatments35 stated that, 
although combination treatments (ie. CBT, medications) 
might appear more efficacious in the short term, in 
the long term, CBT alone was more effective than 
combination treatments or medication alone. 
 The major limitation of CBT as a treatment has been its 
limited availability. Not all psychologists and psychiatrists 
offer CBT, and specialists may not be available to patients 
due to location or cost. Few GPs currently use CBT in 
their practices, but there are educational and financial 
structures available for GPs to use focussed psychological 
strategies (FPS) (or refer to allied health providers to 
provide FPS) under the Better Outcomes in Mental 
Health Initiative (see Resources). Focussed psychological 
strategies – utilising breathing/relaxation exercises, 
cognitive restructuring and graded exposure36 – are key 
elements of CBT programs and can be delivered within 
the general practice setting. 
Focussed psychological strategies in PD
Breathing/relaxation exercises
Simple slow breathing or graded muscle relaxation 
techniques can greatly assist patients, particularly 
those who are chronic overbreathers and/or suffer 
from significant discomfort due to muscle tension. 
These techniques are relatively easy to teach 
patients (assisted by the use of handouts) and can 
(and should) be practised by the patient between GP 
consultations.37
Cognitive restructuring
Cognitive restructuring involves working collaboratively 
with the patient to identify unhelpful and inaccurate 
cognitions (eg. ‘I’m about to die’) and ultimately to 
replace those with more realistic/accurate ones through a 
process of reasoned debate and basic evidence gathering. 
Commonly, worksheets are used to help record, monitor 
and address panic related cognition (Table 2). 
Graded exposure
Graded exposure refers to (re)introducing the patient to 
feared stimuli in order that they may begin testing and 
evaluating their anxiety control skills when faced with 
anxiety triggering stimuli. With PD, the feared stimuli 
are typically bodily sensations associated with panic 
(eg. racing heart, shortness of breath, sweating). These 
sensations may be produced in a safe setting and aim 
Table 2. Example worksheet for cognitive restructuring
Situation (Describe the panic  Waiting at the supermarket  
arousing situation) checkout 
Feelings (How did you feel  Anxious, panicky, scared 
in this situation?) 
Thoughts What were you thinking in  Rebuttal (What evidence is there  
 this situation? ‘against’ this thought?)
 
 I’m going to do  I haven’t done anything crazy before 
 something crazy despite having dozens of panic attacks
 
 I’m going to have to leap  I’ve always managed to either see the 
 over the counter to get out anxiety through or leave normally
 
 If I don’t get out I will  I haven’t ever ‘lost it’ before, and even if 
 ‘lose it’ I have a panic attack, it will eventually 
  go away
 
 I am losing my mind  My GP tells me there is no evidence 
that having panic attacks leads to 
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to ‘decondition’ the patient to anxious responding. 
 The process involves exposing the patient to 
progressively more challenging types and degrees 
of panic invoking stimuli as are relevant to each 
particular patient. For example, for the patient who 
particularly fears a racing heart, graded exposure might 
utilise gentle exercise as the means to exposing that 
patient to such sensations, with increasingly active 
exercise prescribed as the patient is able to tolerate 
preceding levels. Alternatively, for the patient who 
fears dizziness, a short hyperventilation exercise can 
be used to produce the feared sensations. The patient 
not only learns more about their responding through 
these exercises, but is also conditioning him/herself to 
respond in a nonanxious way to the feared sensations. 
 The worksheet shown in Table 3 is an example of 
a patient’s ‘hierarchy of fear’ whereby anxiety triggers 
are external or situational (in contrast to internal or 
physical triggers). This patient would typically benefit 
from exposure to the stimuli listed in this hierarchy 
sequentially from least feared to most feared, with 
progression to the next level only pursued following 
successful anxiety control at the previous step. This 
type of process is obviously pursued by the patient 
between consultation times, with the GP taking on a 
coaching and monitoring role.
Pharmacological management
The institution of pharmacological treatment for patients 
with panic disorder requires sensitivity and patience. 
There needs to be plenty of time provided to discuss 
the medications and their side effects and support 
given in making the decision to take medication. Being 
already focussed on their physical status, starting a 
medication can often increase this awareness and even 
minor side effects can be interpreted catastrophically 
leading to premature cessation of treatment. 
 Giving away control to another individual by taking 
a medication is often extremely challenging for 
patients with PD. Engaging patients in the decisions 
regarding their treatment by providing patient education 
is important (see Resources). By encouraging the 
patient to return to discuss their overall treatment plan, 
including medication, at their next visit after reviewing 
the information engages the patient as an informed 
consumer and aids compliance. For many people with 
PD there is a reluctance to take antidepressants. A 
caring, careful approach with psycho-education and a low 
starting dose can lead to excellent outcomes for people 
who are often quite severely disabled from their illness.
SSRIs
First line medications for treatment of PD are the 
selective serotonin reuptake inhibitors (SSRIs).38 
Evidence as to whether SSRIs are any better than 
tricyclic antidepressants (TCAs), BZDs, or monoamine 
oxidase inhibitors (MAOIs) is unclear, and so it is 
best to assume that medications from these four 
classes are about equal in efficacy.39 However, SSRIs 
have higher compliance and fewer adverse effects 
than other drugs available and therefore are the 
treatment of first choice.40  
 There is good evidence for the efficacy of fluvoxamine 
(100–300 mg/day), fluoxetine (20–40 mg/day), paroxetine 
(40 mg/day) citalopram (20–40 mg/day) and sertraline 
(50–200 mg/day).40 Doses required to treat PD are 
generally higher than those required for depression. 
 Major side effects of SSRIs are nausea, diarrhoea, 
tremor, increased sweating, insomnia or drowsiness 
(commonly described as slowness or fuzziness of 
thinking) and sexual dysfunction. Some people 
experience an increase in anxiety initially with SSRIs. 
This is often a combination of a side effect of the 
medication and the underlying anxiety/hypervigilance 
of the patient themself. At the commencement of 
treatment, the frequency, severity and nature of panic 
attacks may change, and warning the patient of this 
can alleviate anxiety. Consequently, it is advisable to 
start all patients with PD at a low dose (commonly 
Table 3. Example of a ‘hierarchy of fear’ as used to guide graded 
exposure to anxiety provoking stimuli
1. Waiting at the supermarket checkout High anxiety
2. Walking through the supermarket aisles
3. Entering the supermarket
4. Parking in the supermarket car park
5. Driving to the supermarket
6. Getting in the car to go to the supermarket
7. Writing up a shopping list Low anxiety
Table 4. Useful questions for use as part of assessment for panic disorder
• Describe a typical anxiety/panic episode?
• How often do the panic attacks occur?
•  Does the panic occur spontaneously or in reaction to some place, person 
or event?
• What were your thoughts during the panic attack?
• Are you avoiding any places or situations for fear of having a panic attack?
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half the normal starting dose) and to go slow, gradually 
increasing to a therapeutic dose according to the 
patient's tolerance. Most patients will be taking a 
therapeutic dose within 10–20 days. 
 Antidepressants can take longer to take effect in 
patients with PD than for depression (typically 4–6 
weeks). If a patient has failed to respond to treatment 
at maximum tolerated dose for 8–12 weeks, then 
change to another SSRI or TCA, or add CBT, and 
consider referral to a psychiatrist. The SSRIs can also 
have significant withdrawal effects (especially anxiety) 
if they are ceased suddenly, and patients should be 
cautioned regarding this.41,42 
Other antidepressants
The tricyclic antidepressants are effective, but there 
are high drop out rates due to side effects. Imipramine 
at a dose of 100–225 mg/day is effective. The MAOIs 
are also effective, but should be reserved for treatment 
resistant cases due to side effects and the need for 
a tyramine free diet. There is insufficient evidence 
available on the efficacy of venlafaxine or moclobemide 
in PD.40 Buspirone and beta blockers have not been 
shown to be of use.43
 Interestingly, in view of how common CBT/medication 
combination therapy is, there is insufficient evidence 
regarding combination therapy of CBT with SSRIs, TCAs 
or MAOIs.40 Pharmacotherapy should be the first line of 
treatment in more severe cases, especially where there 
is comorbid major depression or PTSD.22
Benzodiazepines 
There remains significant controversy about the use 
of BZDs in the treatment of PD. Benzodiazepines are 
moderately effective and are better tolerated than 
the older antidepressants. There is however a high 
rate of relapse upon cessation. The risks with the 
BZDs are well known, including iatrogenic dependence, 
drowsiness and impairment of concentration and motor 
performance. They have been found to interfere with 
the efficacy of CBT at both 3 and 24 months follow 
up.44 Clinically, it is best to avoid using short acting 
BZDs such as alprazolam as they need to be taken 
three times per day to avoid withdrawal phenomena 
– and this is not practical for most patients. Withdrawal 
from short acting BZDs has also been shown to be 
more difficult.40 Benzodiazepines are of particular use in 
two situations:
• where a person has such severe illness they are at 
risk of losing their job, or unable to leave the house 
to come to an appointment or go to hospital without 
some temporary relief.39 The risk here is that patients 
may attribute all the benefits to the BZD and not to 
therapies such as SSRIs or CBT. Withdrawal may 
be difficult even after short term use, and the BZD 
may interfere with the efficacy of CBT by decreasing 
motivation to complete the CBT program,45 and
• in chronic treatment resistant PD as an augmenting 
agent where there has only been a partial response 
to antidepressants and CBT. In this situation, as long 
as there is no history of drug dependence or severe 
personality disorder, patients can be maintained long 
term with good clinical effect. There is no evidence 
for dependence or significant escalation in doses of 
BZDs being required to maintain a clinical response in 
patients with panic disorder.39,46 
In the majority of patients, once the nature of the 
illness and the treatment approach is explained, they 
are generally content not to take BZDs and wait for 
the onset of effect of either the antidepressants and/or 
CBT. Commonly, patients are already on a BZD when 
seen initially, and a slow withdrawal of the BZD (over 
2–4 months depending on dose) while instituting other 
treatment is appropriate. 
 Patients also use BZDs as a ‘safety’ behaviour. 
It is not uncommon for patients to find it reassuring 
to have a tablet of alprazolam or diazepam in their 
Table 5. Examinations and investigations for patients with suspected PD 
Examinations
General appearance Signs of anxiety, anaemia, or evidence of  
 substance abuse
Vital signs Pulse irregularities, fever, blood pressure,   
 tachypnoea
Cardiovascular Arrhythmias, ischaemic heart disease, cardiac 
 failure, valvular disease
Respiratory Local or generalised lung disease
Thyroid Thyroid examination including signs of 
 hyperthyroidism or thyroid eye disease
Neurological Focal neurological signs
Investigations
• full blood examination
• urea, electrolytes and creatine
• liver function tests
• fasting glucose
• thyroid function tests
•  with discretion: electrocardiogram (especially in those with chest pain 
as a prominent symptom), chest X-ray, echocardiogram, CT brain, 
electroencophelogram, Holter monitor, urine catecholamines, drug screen
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pocket or purse just in case they suffer a panic attack 
when away from home or alone. Many, who otherwise 
have recovered from their PD and agoraphobia, will 
still be carrying a tablet ‘just in case’. They are often 
reluctant to admit this unless asked directly, and should 
be supported to venture through life without their 
reassuring ‘friend’.
 The evidence is unclear as to how long 
medications should be continued. In general, continue 
antidepressants for 12 months and then slowly withdraw 
over at least 1 month. Antidepressants should be 
continued until the patient has been panic free for at 
least 6 months and avoidance behaviour extinguished. 
They should not be ceased when significant intercurrent 
psychosocial stressors are present. If BZDs have been 
used, continue treatment until the patient has been 
panic free for 6 months then withdraw slowly over 3–6 
months.47,48 
Conclusion 
Panic disorder is a common psychological condition 
distinguished by recurrent, unexpected panic attacks 
that cause significant distress and impairment for the 
patient. Both genetic/familial and individual specific 
environmental factors, as well as cognitive and 
behavioural characteristics, appear to play a role in 
its aetiology. General practitioners are typically at the 
‘front line’ for the identification and management of 
PD, and fortunately effective treatments are available 
including lifestyle changes, psychological strategies and 
pharmacotherapy. Key steps in patient management 
include: thorough assessment for possible organic 
causes; patient education; and developing a 
management plan in light of patient preferences and 
needs, available resources both within the general 
practice setting, and externally through specialist 
mental health support. 
Summary of important points
• GPs are commonly the first contact for patients 
seeking assistance with panic symptomatology.
• Panic disorder is a positive diagnosis rather than a 
diagnosis of exclusion.
• Management of PD involves careful and empathic 
education, lifestyle changes, specific psychological 
techniques, the judicious use of pharmacotherapy, 
and ongoing monitoring and review.  
• CBT is the treatment of choice, and first line 
medication are the SSRIs.
Resources
•   Aisbett B. Living with it: a survivors guide to panic attacks. 
Australia: Harper Collins. Perennially popular, simple, easy 
to read overview of panic disorder written by an ex-sufferer 
using illustrations and cartoons to help explain ‘it’ (PD)
•   Barlow DM, Craske MG. Mastery of your anxiety and panic. 
3rd ed. New York: Graywind, 2000. A comprehensive multi-
element CBT treatment manual/workbook for therapists and 
patients
•  Monash University. Panic information and treatment 
resource: ‘Panic online’: www.med.monash.edu.au/non-
cms/mentalhealth/paniconline/ A useful and free source of 
quality psycho-educational material about PD
•   The Royal Australian and New Zealand College of 
Psychiatrists. Clinical practice guidelines: www.ranzcp.org/
publicarea/cpg.asp#cc Free, quality source of information 
for clinicians and consumers/carers
•   Anxiety Disorders Association of Victoria: www.adavic.org/ 
Useful information regarding PD as well as links to other 
resources 
•   Information on the Better Outcomes in Mental Health 
Initiative: www.racgp.org.au/mentalhealth 
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